A Century‑Old TB Shot Shows New Life in the Fight Against Diabetes

When you hear “vaccine,” the first thing that probably pops into your head is Covid‑19 or perhaps the seasonal flu. Yet, tucked away in medical textbooks is a 100‑year‑old inoculation—Bacillus Calmette‑Guérin, or BCG—originally crafted to fend off tuberculosis.

In a surprising twist, researchers have now turned that old‑school shot toward a completely different foe: type‑1 diabetes. The disease, an autoimmune attack on insulin‑producing cells, has long defied a cure, leaving patients to juggle daily insulin injections and constant glucose monitoring.

What sparked this cross‑over? A series of small, yet rigorously designed clinical trials. Volunteers with newly diagnosed type‑1 diabetes received a single dose of BCG, and over the following months their bodies began to do something unexpected—shift their metabolism from glucose to sugar‑derived fats, a process called “glycolysis reversal.”

That metabolic switch is more than a biochemical curiosity. By rerouting how cells burn energy, the vaccine appears to lower the demand for insulin, easing the pressure on the already‑strained pancreas. In some participants, blood‑sugar levels dropped enough that the dose of external insulin could be trimmed.

Scientists say the magic lies in BCG’s ability to rev up a particular set of immune cells called regulatory T‑cells. Think of them as the peacekeepers of the immune system, coaxing rogue attackers to stand down. When BCG boosts these cells, the autoimmune onslaught on the pancreas eases, granting it a slim chance to recover.

The findings are still early‑stage, and the researchers caution that BCG is not a silver bullet. Larger, double‑blind trials are already in the pipeline to confirm safety, optimal dosing, and long‑term outcomes. But the notion that a vaccine, already on the World Health Organization’s essential medicines list, could be repurposed for diabetes is thrilling.

Beyond diabetes, this line of work opens a door to a broader idea: using old vaccines as modulators of the immune system for a host of chronic diseases. If BCG can gently reset the immune balance, perhaps other century‑old shots could be coaxed into new roles.

For now, patients and clinicians alike watch with hopeful eyes. A simple injection that could someday reduce the daily grind of insulin shots would be nothing short of a paradigm shift—proof that sometimes, the best innovations are hidden in plain sight.